Renal Business Today

IV Iron

Canada Approves Feraheme to Treat CKD Patients

LEXINGTON, Mass.—Health Canada, on Dec. 8 granted marketing approval to AMAG Pharmaceuticals and Takeda Canada for the iron drug Feraheme. ...More
December 12, 2011
Posted in News, Business, Clinical & Pharma, Government & Regulation
Dialysis Bundle Changes ESA, IV Iron Use

EXTON, Pa.—Nephrologists have reported changes in the use of erythropoietin stimulating agents (ESAs) and intravenous (IV) iron in the management of renal anemia in dialysis patients due to the new dialysis bundled payment system, according to a new report from BioTrends ...More
May 2, 2011
Posted in News, Clinical & Pharma, Practice Management
Sanofi-Aventis Releases New Ferrlecit Formulation

BRIDGEWATER, N.J.—In response to customer feedback, sanofi-aventis has started to sell its iron drug Ferrlecit in a new vial formulation, which is replacing the older ampule version in order to avoid and potential safety issues. ...More
April 22, 2011 By Keith Chartier
Posted in Articles, Business, Clinical & Pharma, Government & Regulation, Practice Management
FDA Approves Generic Ferrlecit

MORRISTOWN, N.J.—The U.S. Food and Drug Administration (FDA) has approved GeneraMedix Inc.’s generic version of sanofi aventis’ iron drug Ferrlecit. ...More
March 31, 2011
Posted in News, Clinical & Pharma, Government & Regulation
Fresenius, Galenica Form Renal Pharma Company

BAD HOMBURG, Germany—Fresenius Medical Care AG and Galenica Ltd. announced Dec. 1 the formation of a new renal pharmaceutical company designed to develop and distribute on a worldwide basis products to treat iron deficiency anemia and bone mineral metabolism for ...More
December 1, 2010
Posted in News, Business
Use of Anemia Drugs in CKD Stabilizing

EXTON, Pa.— The use of erythropoietin-stimulating agents (ESAs) in patients with chronic kidney disease not on dialysis (CKD-ND) is showing signs of stabilization, according to the latest survey released by BioTrends Research. ...More
October 27, 2010
Posted in News, Clinical & Pharma, Practice Management
Japan Sees EPO Dose Reduction with Bundling

BRUSSELS, Belgium—More than four years after Japan implemented a payment policy that bundled erythropoietin-stimulating agents with dialysis, the country has seen a reduction in ESA use and an increase in the prescription of intravenous iron, according to an article ...More
October 25, 2010
Posted in News, Clinical & Pharma
FDA Considers Limiting Anemia Drug Use for Kidney Disease

Because widely used anemia drugs may double the risk of stroke in patients with kidney disease, the Food and Drug Administration is considering new restrictions on them. On Thursday, the FDA posted a safety review of three medications from Amgen Inc., Epogen, Procrit, and ...More
October 14, 2010
Posted in News, Clinical & Pharma
AMAG, FDA To Meet About Feraheme Safety Issues

CAMBRIDGE, Mass.—AMAG Pharmaceuticals was forced to pull out of a business conference due to a safety meeting it must have with the U.S. Food and Drug Administration regarding the iron drug Feraheme, according to a regulatory filing. ...More
September 21, 2010
Posted in News, Government & Regulation
Global IV Iron Drug Market to Reach $1.6 Billion by 2015

SAN JOSE, Calif.—The global market for Intravenous (IV) Iron Drugs is forecast to reach $1.6 billion by the year 2015, according to a report market research company Global Industry Analysts Inc. (GIA). ...More
August 10, 2010
Posted in News, Business, Clinical & Pharma